Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Glatiramer acetate in multiple sclerosis.

Domenico M Mezzapesa¹, Marco Rovaris, Massimo Filippi

¹Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy.

Expert Review of Neurotherapeutics

|July 20, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beyond GLM: Inter-Subject Variability as a Complementary Approach to Detect Longitudinal Changes in Emotion Processing in Multiple Sclerosis.

Journal of imaging·2026

Same author

Serum miR-199a-3p and miR-103a-3p are possible biomarkers for the onset of multiple sclerosis.

Scientific reports·2026

Same author

Efficacy of traditional swallowing therapy plus neuromuscular electrostimulation in multiple sclerosis: A randomized controlled trial.

Multiple sclerosis and related disorders·2026

Same author

Optic nerve sheath diameter ultrasonography and invasive cisternal pressure monitoring for risk stratification and surgical selection in idiopathic intracranial hypertension.

Neurosurgical focus·2026

Same author

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

JAMA network open·2025

Same author

Sex-Specific Effects of <i>AQP4</i> Gene Polymorphisms on Multiple Sclerosis Susceptibility and Response to Multidisciplinary Rehabilitation.

International journal of molecular sciences·2025

Same journal

An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache.

Expert review of neurotherapeutics·2026

Same journal

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026

Same journal

Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions.

Expert review of neurotherapeutics·2026

Same journal

The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis.

Expert review of neurotherapeutics·2026

Same journal

Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review.

Expert review of neurotherapeutics·2026

Same journal

Clinical efficacy of lacosamide in neuropathic pain: a systematic review of randomized controlled trials.

Expert review of neurotherapeutics·2026

See all related articles

Glatiramer acetate (Copaxone) is a multiple sclerosis treatment that primarily targets inflammation. Emerging evidence suggests it may also offer neuroprotective benefits, impacting its role in managing this chronic neurological condition.

Area of Science:

Immunology
Neuroscience
Pharmacology

Background:

Relapsing-remitting multiple sclerosis (RRMS) is a chronic inflammatory neurological disease.
Glatiramer acetate (Copaxone) is an established disease-modifying therapy for RRMS, primarily targeting inflammation.
Recent research indicates potential neuroprotective effects of glatiramer acetate beyond its anti-inflammatory action.

Purpose of the Study:

To critically review clinical trial data and other studies on glatiramer acetate in RRMS.
To evaluate the evidence for glatiramer acetate's neuroprotective properties.
To assess the current position of glatiramer acetate within the landscape of approved RRMS treatments.

Main Methods:

Comprehensive literature search of clinical trials and relevant studies.

Related Experiment Videos

Critical analysis of existing data on glatiramer acetate efficacy and mechanisms.

Comparative assessment against other disease-modifying treatments for RRMS.

Main Results:

Glatiramer acetate effectively reduces inflammatory relapses in RRMS.
Emerging evidence suggests glatiramer acetate may confer neuroprotection, potentially slowing disease progression.
Its therapeutic profile positions it as a valuable option among multiple RRMS treatment strategies.

Conclusions:

Glatiramer acetate remains a key treatment for RRMS, addressing its inflammatory aspects.
The potential neuroprotective effects warrant further investigation and may enhance its clinical utility.
Its role in comprehensive RRMS management includes both anti-inflammatory and potential neuroprotective benefits.